A systematic review evaluating the efficacy and factor consumption of long-acting recombinant factor VIII products for the prophylactic treatment of hemophilia A
Zentrum für Labormedizin, Hämostase- und Hämophilie-Zentrum, St. Gallen, Switzerland. CSL Behring, King of Prussia, PA, USA. Changhua Christian Hospital, Changhua, Taiwan. Valley Children's Healthcare and Hospital, Madera, CA, USA.
Aims: Long-acting (LA) recombinant FVIII (rFVIII) products with extended dosing intervals have been developed for the treatment of hemophilia A; however, no direct head-to-head trial has been conducted to compare the efficacy of these products.Materials and methods: A systematic literature search was conducted to identify published Phase III clinical trials of prophylactic LA rFVIII treatment in previously treated patients aged
≥12 years, with moderate-to-severe hemophilia A (endogenous FVIII levels ≤2%). Studies that did not meet these criteria, or did not report the included outcomes, were excluded. Bleeding rates and consumption were extracted and summarized; only data for the dosing frequencies indicated in the US product labels (which are similar to those indicated in the European Medicines Agency labels) were included.Results: Five articles met the inclusion criteria; these studies only included patients with severe hemophilia A. Treatment length, reported outcomes and dose (range: 20-65 IU/kg) varied between studies. Median annualized bleeding rate (ABR) (IQR) reported in the relevant studies was 1.14 (0.00, 4.30), rVIII-SingleChain 2 or 3 times weekly; 1.6 (0.0, 4.7), rFVIIIFc 2 times weekly followed by every 3-5 days; 1.9 (0.0, 5.8), BAX855 2 times weekly; 1.18 (0.00, 4.25), N8-GP every 4 days; 1.9 (0.0, 5.2) and 4.1 (2.0, 10.6), BAY 94-9027 2 times weekly for the cohort who experienced >1 or <1 bleed in the study run-in phase, respectively. Median spontaneous ABR was 0.0 across studies reporting relevant data. Reported consumption was comparable among all LA products.Limitations: The primary limitation of this systematic review was the variation in study design and not all studies reported all desired outcomes, which limited the quantity of data available.Conclusions: This systematic review identified pivotal trial data for LA rFVIII products. Real-world evidence are needed to understand how these products perform in clinical practice.
